David N Haney

Title: The Innovative Contributions of David N. Haney

Introduction

David N. Haney is a notable inventor based in Mercer Island, WA (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of cyclic peptide compounds. With a total of 2 patents to his name, Haney's work focuses on innovative methods for inhibiting cancer growth and metastasis.

Latest Patents

Haney's latest patents include a method of using cyclic peptides to inhibit binding to the urokinase-type plasminogen activator receptor. These cyclic peptide compounds consist of 11 amino acids joined by a linking unit, with a specific linear dimension that is crucial for their function. The patents disclose methods for using these cyclic peptide compounds and compositions containing them to inhibit the growth or metastasis of cancerous tumors. Another patent details cyclic peptides that bind to the urokinase-type plasminogen activator, emphasizing their utility in cancer treatment.

Career Highlights

David N. Haney is currently associated with Angstrom Pharmaceuticals, Inc., where he continues to advance his research and development efforts. His work has the potential to impact cancer therapies significantly, showcasing his dedication to improving medical outcomes.

Collaborations

Haney collaborates with esteemed colleagues such as Terence R. Jones and Janos Varga, contributing to a dynamic research environment that fosters innovation.

Conclusion

David N. Haney's contributions to the field of pharmaceuticals through his innovative patents and collaborative efforts highlight his commitment to advancing cancer treatment. His work exemplifies the importance of research and innovation in addressing critical health challenges.